These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23032938)

  • 1. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2.
    Pietsch M; Viht K; Schnitzler A; Ekambaram R; Steinkrüger M; Enkvist E; Nienberg C; Nickelsen A; Lauwers M; Jose J; Uri A; Niefind K
    Bioorg Chem; 2020 Mar; 96():103608. PubMed ID: 32058103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
    Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CK2α and CK2α' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives.
    Janeczko M; Orzeszko A; Kazimierczuk Z; Szyszka R; Baier A
    Eur J Med Chem; 2012 Jan; 47(1):345-50. PubMed ID: 22115617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
    Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
    J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
    Leung KK; Shilton BH
    Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
    Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
    Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
    Bollacke A; Nienberg C; Borgne ML; Jose J
    J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.
    Laudet B; Barette C; Dulery V; Renaudet O; Dumy P; Metz A; Prudent R; Deshiere A; Dideberg O; Filhol O; Cochet C
    Biochem J; 2007 Dec; 408(3):363-73. PubMed ID: 17714077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin.
    Raaf J; Klopffleisch K; Issinger OG; Niefind K
    J Mol Biol; 2008 Mar; 377(1):1-8. PubMed ID: 18242640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
    Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
    Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
    Schnitzler A; Niefind K
    Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
    Sekiguchi Y; Nakaniwa T; Kinoshita T; Nakanishi I; Kitaura K; Hirasawa A; Tsujimoto G; Tada T
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2920-3. PubMed ID: 19414254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives.
    Chojnacki K; Wińska P; Skierka K; Wielechowska M; Bretner M
    Bioorg Chem; 2017 Jun; 72():1-10. PubMed ID: 28340404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selectivity of inhibitors of protein kinase CK2: an update.
    Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
    Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First inactive conformation of CK2 alpha, the catalytic subunit of protein kinase CK2.
    Raaf J; Issinger OG; Niefind K
    J Mol Biol; 2009 Mar; 386(5):1212-21. PubMed ID: 19361447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
    Vahter J; Viht K; Uri A; Enkvist E
    Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.
    Cozza G; Gianoncelli A; Bonvini P; Zorzi E; Pasquale R; Rosolen A; Pinna LA; Meggio F; Zagotto G; Moro S
    ChemMedChem; 2011 Dec; 6(12):2273-86. PubMed ID: 21972104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.